Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lonaprisan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Lonaprisan (ZK 230211, BAY86-5044) | DRUG | 25 mg daily oral treatment |
Inclusion Criteria: * Postmenopausal women defined as: aged \>/= 50 years with amenorrhea for at least 12 months or aged \< 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (\> 40 mIU/ml) or having undergone bilateral oophorec...
Top 20 of 92 competitors
Lonaprisan is an investigational small molecule being developed for the treatment of metastatic breast cancer. It is intended for postmenopausal women with this condition. The drug is currently in clinical development and has not been approved by regulatory authorities.
Lonaprisan is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded under the ticker symbol BAYRY on the over-the-counter market. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with metastatic breast cancer.
Lonaprisan is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a controlled, randomized study involving 68 postmenopausal women with metastatic breast cancer. The drug remains investigational and is not yet approved for commercial use.
Lonaprisan has been studied in one clinical trial with the identifier NCT00555919. This Phase 2 trial, titled 'ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer,' was completed and enrolled 68 female participants aged 18 years and older. The study was conducted across multiple European countries.
Yes, Lonaprisan is also known as ZK 230211. The clinical trial NCT00555919 uses this alternative name in its title. This designation helps identify the drug in research databases and scientific literature related to its development for metastatic breast cancer.